Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody
Matas-Céspedes A, Crespo AV, Rodriguez V, et al.
Key Points:
Authors present first preclinical in vivo results of Daratumumab (DARA), a human CD38 antibody, in mouse models of MCL, transformed FL(tFL) and CLL
DARA completely abolished tumor growth of MCL (REC cell line) and tFL (RL cell line) in prophylactic setting
In therapeutic setting, DARA: induced total tumor regression of (4/6) REC tumors; reduced 60% of tumor growth tFL (RL cell line)
In CLL, DARA significantly reduced migration to spleen; however migration to BM not affected
7/8 mice (in DARA treated group) survival extended up to day 90; compared to mice treated with control IgG which started to lose weight and showed signs of disease between days 30-40 and were sacrificed for ethical reasons.
Implications:
- DARA demonstrated strong in vivo activity in immunocompromised mouse models of MCL, tFL and CLL cell lines and interfered with homing of primary CLL cells to spleen.
View the original abstract on the ASH website.
